|  | Monoclonal antibodies are made by cells which all derive from the same parent cell. They bind very specifically to a single protein. Current research is investigating their clinical application for targeted delivery of drugs to leukaemic cells and to purify cells used for bone marrow and stem cell transplants.
 | Campath |
Campath is a monoclonal antibody (MAb) for the treatment of patients with B-CLL who have been treated with alkylating agents such as chlorambucil and whose disease no longer responds to fludarabine. Campath recognises and binds to a marker (molecule) called CD-52 on the surface of CLL cells. This marks the cell for destruction by the immune system.
| Free full text papers about Campath |
 | | Immunotherapy of Non-Hodgkin's lymphomas
Press, O. W., Leonard, J. P., Coiffier, B., Levy, R., and Timmerman, J.
Hematology (Am.Soc.Hematol Educ.Program.) 2001 221-40, |
| Rituximab |
Rituximab, also known as MabThera, is another example of a monoclonal. It recognises a cellular marker called CD-20 found on nearly all B-lymphocytes and most cancerous cells in B-cell lymphomas. Rituximab is currently licensed in the UK for use in relapsed low-grade follicular lymphoma. |
| |
| |
